92 related articles for article (PubMed ID: 31359385)
21. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
23. Proteome profiling of low grade serous ovarian cancer.
Zadeh Fakhar HB; Zali H; Rezaie-Tavirani M; Darkhaneh RF; Babaabasi B
J Ovarian Res; 2019 Jul; 12(1):64. PubMed ID: 31315664
[TBL] [Abstract][Full Text] [Related]
24. Proteomic analysis of human epithelial ovarian cancer xenografts in immunodeficient mice exposed to chronic psychological stress.
Gao J; Gao G; Zhang Y; Wang F
Sci China Life Sci; 2011 Feb; 54(2):112-20. PubMed ID: 21318480
[TBL] [Abstract][Full Text] [Related]
25. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
Liu YB; Mei Y; Long J; Zhang Y; Hu DL; Zhou HH
J Exp Clin Cancer Res; 2018 Aug; 37(1):182. PubMed ID: 30075819
[TBL] [Abstract][Full Text] [Related]
26. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
[TBL] [Abstract][Full Text] [Related]
27. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.
Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE
Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453
[TBL] [Abstract][Full Text] [Related]
28. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach.
Strouhalova D; Macejova D; Mosna B; Bobal P; Otevrel J; Lastovickova M; Brtko J; Bobalova J
Toxicol Lett; 2020 Jan; 318():22-29. PubMed ID: 31634547
[TBL] [Abstract][Full Text] [Related]
30. 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds.
Guidi F; Puglia M; Gabbiani C; Landini I; Gamberi T; Fregona D; Cinellu MA; Nobili S; Mini E; Bini L; Modesti PA; Modesti A; Messori L
Mol Biosyst; 2012 Apr; 8(4):985-93. PubMed ID: 22134777
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids.
Peng X; Yun D; Christov K
Int J Oncol; 2004 Oct; 25(4):961-71. PubMed ID: 15375546
[TBL] [Abstract][Full Text] [Related]
32. Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses.
Zhang Z; Qin K; Zhang W; Yang B; Zhao C; Zhang X; Zhang F; Zhao L; Shan B
J Ovarian Res; 2019 Mar; 12(1):29. PubMed ID: 30917846
[TBL] [Abstract][Full Text] [Related]
33. Comparative Proteomics of Chromium-Transformed Beas-2B Cells by 2D-DIGE and MALDI-TOF/TOF MS.
Lu J; Tang M; Liu Y; Wang J; Wu Z
Biol Trace Elem Res; 2018 Sep; 185(1):78-88. PubMed ID: 29340859
[TBL] [Abstract][Full Text] [Related]
34. Proteomic comparison of two-dimensional gel electrophoresis profiles from human lung squamous carcinoma and normal bronchial epithelial tissues.
Li C; Zhan X; Li M; Wu X; Li F; Li J; Xiao Z; Chen Z; Feng X; Chen P; Xie J; Liang S
Genomics Proteomics Bioinformatics; 2003 Feb; 1(1):58-67. PubMed ID: 15626334
[TBL] [Abstract][Full Text] [Related]
35. KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-β1 expression.
Liang S; Yao Q; Wei D; Liu M; Geng F; Wang Q; Wang YS
J Cell Biochem; 2019 Jan; 120(1):493-506. PubMed ID: 30277596
[TBL] [Abstract][Full Text] [Related]
36. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
37. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract][Full Text] [Related]
38. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
[TBL] [Abstract][Full Text] [Related]
40. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.
Lemaire R; Menguellet SA; Stauber J; Marchaudon V; Lucot JP; Collinet P; Farine MO; Vinatier D; Day R; Ducoroy P; Salzet M; Fournier I
J Proteome Res; 2007 Nov; 6(11):4127-34. PubMed ID: 17939699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
